AlphAIalphai — Financial news for AI agents
pulpapernews.comJUN 32 min readLow

Automated zeta potential measurement from Emtec at show

Emtec Electronic will attend the Paper and Board Technology Kring seminar in Apeldoorn, Netherlands, June 24–25, focused on raw materials and stock preparation. The company, with sales rep Thierry Onder de Linden, plans to showcase its process and quality control systems, including the ACA, EST, FPO, FPA, and CAS. A June 25 talk by Eric Haagen will demonstrate automated online zeta potential measurement to support stable process conditions and real-time chemical and efficiency optimization.

AI DeskJune 3, 2026
Source · pulpapernews.com
AI analysis
Relevance
2/10
Novelty
2/10
Actionability
Low
Sentiment · —
Timing
June 25 presentation at 10am (Netherlands seminar)
Market alignment
Neutral (educational product demo; no market data or guidance)

Background

emtec Electronic is participating in a Paper and Board Technology Kring seminar focused on raw materials and stock preparation; it will present automated online zeta potential measurement.

Why it matters

The article describes a planned demonstration of an analyzer (FPO Fiber Potential Analyzer Online) aimed at stabilizing process conditions and improving quality consistency, but provides no financial metrics, contract awards, or regulatory developments.

Market relevance

Educational/marketing event coverage with no disclosed commercial milestone; unlikely to drive a tradable move in a specific US-listed stock.

Market effects

Sector

Highlights demand for inline/online process analytics in pulp & paper (zeta potential measurement for stock preparation/quality control).

Regional

Netherlands/European paper industry networking; limited direct read-through to public equities.

Global

Niche industrial instrumentation theme; no direct linkage to a specific US-listed issuer in the article.

Alternative perspectives

Contrarian view

Because the piece is a conference/product showcase, it may not translate into near-term revenue or measurable order flow for any public company.

Overlooked factors

No mention of commercial traction (orders, contracts, pricing, customer adoption), so trading impact is likely minimal.

Key entities

  • company
    emtec Electronic

    Exhibiting/testing and analysis systems provider; presenter will demo automated online zeta potential measurement for pulp/paper process control.

Read at source← All news

Related articles

JUN 14
$JNJLow

London startup to trial drug to prevent cancer therapy side-effect ‘cytokine storm’

Poolbeg Pharma, a London startup, said it will trial its oral drug POLB 001 at six NHS hospitals to prevent cytokine release syndrome (CRS) in patients receiving blood cancer immunotherapy. The trial will enroll 30 people treated with Johnson & Johnson’s teclistamab (Tecvayli), led by the University of Manchester and Christie NHS Foundation Trust. Poolbeg expects interim data by end of summer; it estimates a $10bn market potential at $20,000 per treatment.

theguardian.com6 min
JUN 14
$AMGNLow

Here’s Why Amgen (AMGN) is Among the 7 Best Longevity Stocks to Buy Now

Amgen said at the American Diabetes Association 86th Scientific Sessions (June 7, 2026) that Phase 3 VESALIUS-CV subgroup data for Repatha in 6,002 high-risk diabetes patients reduced a composite endpoint (CHD death, MI, ischemic stroke) by 29% vs placebo and reduced a second composite including ischemia-driven revascularization by 21%. Separately, Goldman Sachs cut its AMGN price target to $389 from $425 while keeping a Buy rating, citing an IRS audit dispute disclosed in Q1.

finance.yahoo.com4 min
JUN 14
$METAMed

Meta Quietly Removed Face Recognition From Ray

Meta removed a facial recognition feature (“NameTag”) from the Ray-Ban smart glasses app in June 2026, according to the article. The feature in Meta AI could identify people and pull their Instagram/Facebook profiles without consent or notification. The change followed pressure from 70+ civil rights and privacy groups, which cited risks of street-level identification and surveillance. Meta made no public announcement.

memeburn.com7 min
JUN 14
$LLYMedAI 8/10

Lilly’s Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL

Eli Lilly reported Phase 3 BRUIN CLL-322 results for Jaypirca (pirtobrutinib) plus venetoclax and rituximab versus venetoclax and rituximab alone in relapsed/refractory CLL/SLL. The addition reduced the risk of progression or death by 45% (IRC-assessed PFS: HR 0.55, p=0.0001). Median PFS was not reached vs 39.7 months. Safety showed similar Grade ≥3 AEs. Data will be presented at EHA 2026.

bubblear.com4 min
JUN 14
$LLYMedAI 9/10

Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL

Eli Lilly reported Phase 3 BRUIN CLL-322 results for Jaypirca (pirtobrutinib) plus venetoclax and rituximab versus venetoclax and rituximab alone in relapsed/refractory CLL/SLL. The addition met the primary endpoint, reducing risk of progression or death by 45% (HR 0.55, p=0.0001). Median PFS was not reached vs 39.7 months. Safety was similar; OS not mature. Data will be presented at EHA 2026.

prnewswire.com6 min
JUN 14
$LEGNMedAI 8/10

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Legend Biotech (NASDAQ: LEGN) reported first clinical proof-of-concept data for LB2501, an in vivo CD19/CD20 dual-targeting CAR-T, in a Phase 1 study for relapsed/refractory B-cell non-Hodgkin lymphoma. At dose level 2 (6 patients), it showed 100% ORR and 83.3% CR after a single infusion, with no DLTs, ICANS, or deaths. CRS/IRR were Grade 1–2. Responses were ongoing; data were presented at EHA 2026.

manilatimes.net4 min